Darzalex multiple myeloma

Darzalex (daratumumab) is used for treating a blood cancer called multiple myeloma. Darzalex may be used to treat multiple myeloma that has never been treated, is relapsed, meaning

Darzalex is the first FDA-approved monoclonal antibody that targets the CD38 protein on the surface of myeloma cells. It is approved for adult patients with myeloma in multiple disease settings, from the newly diagnosed to the relapsed/refractory. Darzalex is administered intravenously.

Files Provincial Funding Summary Daratumumab (Darzalex) Multiple Myeloma (second-line or beyond) - pERC Final Recommendation Daratumumab (Darzalex)

New oral agent shows promise in treatment of relapsed multiple myeloma FDA Approves Three New Treatments for Multiple Myeloma Darzalex-Based

Multiple Myeloma access options Ninlaro (ixazomib). Multiple Myeloma Empliciti (elotuzumab). Multiple Myeloma Darzalex (daratumumab) Blenrep (belantamab

Darzalex (daratumumab) is a highly effective drug used to treat multiple myeloma. Read about who is a candidate, side effects, special warnings. Darzalex is the first FDA-approved monoclonal antibody that targets the CD38 protein on the surface of myeloma cells.

Darzalex Faspro (daratumumab/hyaluronidase-fihj) is used to treat multiple myeloma. There are currently no generic alternatives to darzalex faspro. It may be

Daratumumab (Darzalex) for Myeloma Treatment Another drug, daratumumab (Darzalex), binds to the CD38 marker, which multiple myeloma cells

Darzalex is the first FDA-approved monoclonal antibody that targets the CD38 protein on the surface of myeloma cells. It is approved for adult patients with myeloma in multiple disease settings, from the newly diagnosed to the relapsed/refractory. Darzalex is administered intravenously.